Casein kinase 1α regulates an MDMX intramolecular interaction to stimulate p53 binding

Molecular and Cellular Biology

Volumn 32, Issue 23, 2012, Pages 4821-4832

  Wu, Shaofang ^a   Chen, Lihong ^a   Becker, Andreas ^a   Schonbrunn, Ernst ^a   Chen, Jiandong ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASEIN KINASE IALPHA; PROTEIN MDMX; PROTEIN P53;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; DNA DAMAGE; EMBRYO; IN VITRO STUDY; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; WILD TYPE;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; CASEIN KINASE IALPHA; CELL LINE; CELL LINE, TUMOR; DNA DAMAGE; HUMANS; MICE; MOLECULAR SEQUENCE DATA; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN INTERACTION MAPS; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84871884749     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00851-12     Document Type: Article

References (56)

1. Banin S, et al. 1998. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281:1674-1677.
2. Burke JR, Deshong AJ, Pelton JG, Rubin SM. 2010. Phosphorylationinduced conformational changes in the retinoblastoma protein inhibit E2F transactivation domain binding. J. Biol. Chem. 285:16286-16293.
3. Chehab NH, Malikzay A, Appel M, Halazonetis TD. 2000. Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes Dev. 14:278-288.
4. Chen J, Marechal V, Levine AJ. 1993. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell. Biol. 13:4107-4114.
5. Chen L, Gilkes DM, Pan Y, Lane WS, Chen J. 2005. ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage. EMBO J. 24:3411-3422.
6. Chen L, Li C, Pan Y, Chen J. 2005. Regulation of p53-MDMX interaction by casein kinase 1 alpha. Mol. Cell. Biol. 25:6509-6520.
7. Cheng Q, Chen L, Li Z, Lane WS, Chen J. 2009. ATM activates p53 by regulating MDM2 oligomerization and E3 processivity. EMBO J. 28: 3857-3867.
8. Cheng Q, et al. 2011. Regulation of MDM2 E3 Ligase activity by phosphorylation after DNA damage. Mol. Cell. Biol. 31:4951-4963.
9. Elyada E, et al. 2011. CKIalpha ablation highlights a critical role for p53 in invasiveness control. Nature 470:409-413.
10. Francoz S, et al. 2006. Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc. Natl. Acad. Sci. U. S. A. 103:3232-3237.
11. Gajjar M, et al. 2012. The p53 mRNA-Mdm2 interaction controls Mdm2 nuclear trafficking and is required for p53 activation following DNA damage. Cancer Cell 21:25-35.
12. Gilkes DM, Chen L, Chen J. 2006. MDMX regulation of p53 response to ribosomal stress. EMBO J. 25:5614-5625.
13. Grier JD, Xiong S, Elizondo-Fraire AC, Parant JM, Lozano G. 2006. Tissue-specific differences of p53 inhibition by Mdm2 and Mdm4. Mol. Cell. Biol. 26:192-198.
14. Hu B, Gilkes DM, Chen J. 2007. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX. Cancer Res. 67:8810-8817.
15. Huart AS, MacLaine NJ, Meek DW, Hupp TR. 2009. CK1alpha plays a central role in mediating MDM2 control of p53 and E2F-1 protein stability. J. Biol. Chem. 284:32384-32394.
16. Inuzuka H, et al. 2010. Phosphorylation by casein kinase I promotes the turnover of the Mdm2 oncoprotein via the SCF(beta-TRCP) ubiquitin ligase. Cancer Cell 18:147-159.
17. Jones SN, Roe AE, Donehower LA, Bradley A. 1995. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378:206-208.
18. Kallen J, et al. 2009. Crystal structures of human MdmX (HdmX) in complex with p53 peptide analogues reveal surprising conformational changes. J. Biol. Chem. 284:8812-8821.
19. Kawai H, et al. 2003. DNA damage-induced MDMX degradation is mediated by MDM2. J. Biol. Chem. 278:45946-45953.
20. Knippschild U, et al. 2005. The casein kinase 1 family: participation in multiple cellular processes in eukaryotes. Cell Signal. 17:675-689.
21. Kussie PH, et al. 1996. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274:948-953.
22. LeBron C, Chen L, Gilkes DM, Chen J. 2006. Regulation of MDMX nuclear import and degradation by Chk2 and 14-3-3. EMBO J. 25:1196-1206.
23. Li B, Cheng Q, Li Z, Chen J. 2010. p53 inactivation by MDM2 and MDMX negative feedback loops in testicular germ cell tumors. Cell Cycle 9:1411-1420.
24. Li C, Chen L, Chen J. 2002. DNA damage induces MDMX nuclear translocation by p53-dependent and-independent mechanisms. Mol. Cell. Biol. 22:7562-7571.
25. Li M, Gu W. 2011. A critical role for noncoding 5S rRNA in regulating Mdmx stability. Mol. Cell 43:1023-1032.
26. Li X, et al. 2012. Abnormal MDMX degradation in tumor cells due to ARF deficiency. Oncogene 31:3721-3732.
27. Linares LK, Hengstermann A, Ciechanover A, Muller S, Scheffner M. 2003. HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53. Proc. Natl. Acad. Sci. U. S. A. 100:12009-12014.
28. Linares LK, Scheffner M. 2003. The ubiquitin-protein ligase activity of Hdm2 is inhibited by nucleic acids. FEBS Lett. 554:73-76.
29. Linke K, et al. 2008. Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans. Cell Death Differ. 15:841-848.
30. Maetens M, et al. 2007. Distinct roles of Mdm2 and Mdm4 in red cell production. Blood 109:2630-2633.
31. Marine JC, Jochemsen AG. 2005. Mdmx as an essential regulator of p53 activity. Biochem. Biophys. Res. Commun. 331:750-760.
32. Maya R, et al. 2001. ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. Genes Dev. 15:1067-1077.
33. Mayo LD, Turchi JJ, Berberich SJ. 1997. Mdm-2 phosphorylation by DNA-dependent protein kinase prevents interaction with p53. Cancer Res. 57:5013-5016.
34. Meulmeester E, et al. 2005. Loss of HAUSP-mediated deubiquitination contributes toDNAdamage-induced destabilization of Hdmx and Hdm2. Mol. Cell 18:565-576.
35. Montes de Oca Luna R, Wagner DS, Lozano G. 1995. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378:203-206.
36. Okamoto K, et al. 2005. DNA damage-induced phosphorylation of MdmX at serine 367 activates p53 by targeting MdmX for Mdm2-dependent degradation. Mol. Cell. Biol. 25:9608-9620.
37. Pan Y, Chen J. 2003. MDM2 promotes ubiquitination and degradation of MDMX. Mol. Cell. Biol. 23:5113-5121.
38. Parant J, et al. 2001. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat. Genet. 29:92-95.
39. Pazgier M, et al. 2009. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX.Proc. Natl. Acad. Sci. U. S. A. 106:4665-4670.
40. Pereg Y, et al. 2005. Phosphorylation of Hdmx mediates its Hdm2-and ATM-dependent degradation in response to DNA damage. Proc. Natl. Acad. Sci. U. S. A. 102:5056-5061.
41. Phan J, et al. 2010. Structure-based design of high affinity peptides inhibiting the interaction of p53 with MDM2 and MDMX. J. Biol. Chem. 285:2174-2183.
42. Phillips A, et al. 2010. HDMX-L is expressed from a functional p53-responsive promoter in the first intron of the HDMX gene and participates in an autoregulatory feedback loop to control p53 activity. J. Biol. Chem. 285:29111-29127.
43. Popowicz GM, Czarna A, Holak TA. 2008. Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain. Cell Cycle 7:2441-2443.
44. Shieh SY, Ahn J, Tamai K, Taya Y, Prives C. 2000. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev. 14:289-300.
45. Shieh SY, Ikeda M, Taya Y, Prives C. 1997. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91:325-334.
46. Shinozaki T, Nota A, Taya Y, Okamoto K. 2003. Functional role of Mdm2 phosphorylation by ATR in attenuation of p53 nuclear export. Oncogene 22:8870-8880.
47. Sionov RV, et al. 2001. c-Abl regulates p53 levels under normal and stress conditions by preventing its nuclear export and ubiquitination. Mol. Cell. Biol. 21:5869-5878.
48. Terzian T, et al. 2007. Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development. Mol. Cell. Biol. 27:5479-5485.
49. Vousden KH, Lane DP. 2007. p53 in health and disease. Nat. Rev. Mol. Cell Biol. 8:275-283.
50. Wallace M, Worrall E, Pettersson S, Hupp TR, Ball KL. 2006. Dual-site regulation of MDM2 E3-ubiquitin ligase activity. Mol. Cell 23:251-263.
51. Wang X, Wang J, Jiang X. 2011. MdmX protein is essential for Mdm2 protein-mediated p53 polyubiquitination. J. Biol. Chem. 286:23725-23734.
52. Wang YV, Leblanc M, Wade M, Jochemsen AG, Wahl GM. 2009. Increased radioresistance and accelerated B cell lymphomas in mice with Mdmx mutations that prevent modifications by DNA-damage-activated kinases. Cancer Cell 16:33-43.
53. Wawrzynow B, et al. 2009. A function for the RING finger domain in the allosteric control of MDM2 conformation and activity. J. Biol. Chem. 284:11517-11530.
54. Wu X, Bayle JH, Olson D, Levine AJ. 1993. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7:1126-1132.
55. Xiong S, Van Pelt CS, Elizondo-Fraire AC, Liu G, Lozano G. 2006. Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. Proc. Natl. Acad. Sci. U. S. A. 103:3226-3231.
56. Yu GW, et al. 2006. The central region of HDM2 provides a second binding site for p53. Proc. Natl. Acad. Sci. U. S. A. 103:1227-1232.